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HIV-1 nucleocapsid protein (NC) is a nucleic acid chaperone implicated in several steps of the virus
replication cycle and an attractive new target for drug development. In reverse transcription, NC de-
stabilizes nucleic acid secondary structures and catalyzes the annealing of HIV-1 TAR RNA to its DNA
copy (cTAR) to form the heteroduplex TAR/cTAR. A screening program led to the identiﬁcation of the
plant polyphenols acutissimins A and B as potent inhibitors of NC in different assays. These two ﬂavano-
ellagitannins, which are found in wine aged in oak barrels, exhibited different mechanisms of protein
inhibition and higher potency relatively to their epimers, epiacutissimins A and B, and to simpler
structures notably representing hydrolytic fragments and metabolites therefrom.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).51. Introduction
The urgent need for new anti-HIV drugs is a global concern. Side
effects and the emergence of drug resistance have limited the
therapeutic usefulness of existing drugs, and new targets are ac-
tively explored. An emerging and promising target is represented
by HIV-1 nucleocapsid protein NCp7 (NC), a nucleic acid-binding
protein generated during virion budding by the proteolytic cleav-
age of the Gag precursor. NC is responsible for maturation of the
dimeric RNA, and plays a role in essentially every step of the rep-
lication cycle, from reverse transcription and DNA integration to
packaging and assembly. Furthermore, the strict conservation of
the motifs responsible for NC activity, together with the fact that
most of the known mutations render the virus non-infectious,
raises the possibility that HIV-1 will be unable to generate mutants
resistant to anti-NC drugs.1,2
NC is a relatively small (55 amino acid residues) and highly basic
protein.3 Upon interaction with RNA its ﬂexible N-terminal domain
forms a 310-helix,4 while its core is constituted by two highly
conserved zinc ﬁnger domains (i.e., the N-term. ZF1 and the C-term.7; fax: þ39 (0)498275366
s.quideau@iecb.u-bordeaux.fr
Ltd. This is an open access article uZF2). According to NMR analysis, the ﬁngers fold into very tight,
rigid loops that form a hydrophobic pocket comprising the aro-
matic residues Trp37 and Phe16. The abundance of highly charged
basic residues is responsible for the protein’s broad nucleic acid-
binding activity,6 whereas its intrinsic conformational ﬂexibility
and the hydrophobic nature of ZF residues confer the ability to bind
speciﬁc nucleic acid structures.7,8 In particular, speciﬁc binding is
driven by the formation of relatively strong stacking interactions
between the aromatic residues in the second position of each ZF
(Phe16 in ZF1 and Trp37 in ZF2) and exposed unpaired purines,
especially guanosines.9 In this way, the N-term helix can penetrate
the major groove of DNA/RNA hairpin structures to establish non-
speciﬁc electrostatic interactions with the phosphodiester back-
bone,7 while the ZF domains engage in highly speciﬁc interactions
with the exposed loops of these elements of secondary structure.4
As a result of this dual binding mode, NC can catalyze the folding
and re-folding of nucleic acids by lowering the energy barrier for
dissociation and re-formation of base pairs, promoting the tran-
sient unpairing of bases within helical structures and making them
available for re-annealing in alternative combinations.10e12 Neither
the destabilizing nor the aggregating NC activities rely on ATP
hydrolysis.12,13
NC is required during strand transfer in HIV-1 reverse tran-
scription: the protein catalyzes the melting and annealing of
complementary regions of the viral genome during the complexnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Results of high throughput screening (HTS) experiments aimed at the identi-
ﬁcation of putative inhibitors of NC melting of TAR and cTAR.
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stranded DNA copy of the viral RNA genome. Minus strand transfer
involves the transactivation response element (TAR), an RNA
structure contained in the repeat regions of the long terminal re-
peats (LTR) of the HIV genome, and cTAR, its complementary DNA
sequence. Although thermodynamically favored, their annealing
does not occur extensively in the absence of NC, since both TAR and
cTAR are highly structured regions whose apical parts are deﬁned
by a stem-bulge-loop structure (Fig. 1). Their stable secondary
structures hamper strand transfer and decrease the efﬁciency of
DNA synthesis by the viral reverse transcriptase (RT).3,14 In contrast,
NC protein destabilizes the stem-loop structures and promotes the
formation of the TAR/cTAR hybrid that is required for RT elongation
and synthesis of the DNA copy of HIV genome.15 Interestingly, Tat,
another HIV viral protein targeting TAR, has been recently de-
scribed as a nucleic acid annealer, and shown to promote TAR/cTAR
annealing during reverse trasnscription.16,17Fig. 1. Sequence and secondary structure of oligonucleotides replicating TAR RNA and
cTAR DNA, which were employed in our assays. Their annealing can lead to an ex-
tended TAR/cTAR heteroduplex.
Fig. 3. Structures of the C-glucosidic ellagitannins and related (poly)phenolic com-
pounds analyzed in the NC-inhibition screen.In light of these observations, the inhibition of NC’s chaperone
activity onTAR and cTAR could potentially decrease the efﬁciency of
strand transfer and eventually prevent the completion of reverse
transcription. Any agent capable of interfering with these functions
would provide a new effective approach for inhibiting the replica-
tion cycle ofHIV-1. Althoughnoapproveddrug is currentlyavailable,
different classes have been proposed as possible anti-NC therapeu-
tics. Agents capable of inducing zinc ejection have been studied
extensively, but clinical trials evidenced severe side effects.2 Inter-
calators, such as actinomycin D, have manifested the ability to sta-
bilize dynamic nucleic acid structures, which results in partial
indirect inhibition of NC functions.18 A series of direct antagonists of
NC-binding activity were also identiﬁed, which contain a (poly)hy-
droxylatedxanthenyl ring system.19 In this case, thehydroxyl groups
were shown to be essential for protein binding, possibly through the
formation of relatively stable H-bonds with its core domain.
Searching for new inhibitors, we analyzed a library of over two
hundred molecules belonging to different chemical classes.20 The
assay tested their ability to inhibit NC in vitro by evaluating the IC50
of stem melting inhibition (Fig. 2). The study identiﬁed two classes
of compounds consisting of the intercalating anthraquinones de-
veloped in-house to enhance their nucleic acid-binding proper-
ties20 and the C-glucosidic ellagitannins described in this report.
The inclusion of these plant polyphenols in our screening was
prompted by the structural similarities with the (poly)hydroxylated
xanthenyl compounds proposed as possible NC inhibitors.19 The C-
glucosidic ellagitannins in this study are hydrosoluble polyphenolic
compounds occurring notably in fagaceous hardwoods such as
Quercus (oak) and Castanea (chestnut) species. The most naturally
abundant representatives of this class of ellagitannins are vesca-
lagin (1) and its C1 epimer castalagin (2).21e23 In these compounds,the usual ellagitannin glucopyranose core is replaced by an open-
chain glucose unit, which is rarely encountered in nature. This
structure stems from the formation of a C-aryl glucosidic bond
between the glucose C1 center and the galloyl-derived ring ester-
iﬁed at the glucose O2 position.24,25 The C1-linked O2-galloyl unit is
part of a terarylic nonahydroxyterphenoyl (NHTP) unit, which is
additionally esteriﬁed at the glucose O3 and O5 positions. A biarylic
hexahydroxydiphenoyl (HHDP) unit at the glucose O4 and O6 po-
sitions completes the structure of 1 and 2 (Fig. 3). These stereo-
chemically well-deﬁned biarylic and terarylic units are part of 10-
and 11-membered rings that confer a relative rigidity and well-
organized shape to the overall globular structure of these com-
pounds, which make them particularly well-suited for interacting
with protein targets. Both of these ellagitannins occur in wine as
the result of the aging of this beverage in oak-made barrels. Ves-
calagin (1) does react with grape-derived wine ﬂavan-3-ols such as
(epi)catechin (3) to form the ﬂavano-ellagitannins (epi)acutissi-
mins A and B (4 and 5) (Fig. 3).26,27 In this study, six wine ellagi-
tannins (i.e., 1, 2, 4a/b, and 5a/b)26e29 and their hydrolytic
metabolites were evaluated for their capacity to inhibit NC activity.
The study included also vescalin (6) and castalin (7), two minor C-
glucosidic ellagitannins lacking the HHDP unit at the glucose O4
and O6 positions; catechin (3a); ellagic acid (9), the primary me-
tabolite of the hydrolytic cleavage of the 4,6-HHDP unit of 1 and 2;
Table 1
Inhibition of NC-induced helix destabilization
Compound TAR cTAR
Vescalagin (1) 8.420.43 1.500.57
Castalagin (2) 9.390.84 7.240.26
Catechin (3a) >100 >100
Acutissimin A (4a) 1.460.02 1.180.18
Acutissimin B (4b) 0.810.13 0.950.06
Epiacutissimin A (5a) 0.440.03 1.180.13
Epiacutissimin B (5b) 3.820.40 0.540.01
Vescalin (6) >100 >100
Castalin (7) >100 >100
Gallic acid (8) >100 >100
Ellagic acid (9) 661 381
Urolithin A (10a) >100 >100
Urolithin B (10b) >100 54 1
Urolithin M5 (10c) 432 442
a Data are averagesSEM of three independent experiments.
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(10aec);30e32 and gallic acid (8) (Fig. 3).
Two different assays employing recombinant full-length NC,
TAR RNA, and its complementary cTAR sequencewere performed to
identify inhibitors of NC. The ﬁrst assay, amenable to HTS format,
relied on ﬂuorescently labeled constructs to monitor the melting of
their double-stranded stems. The second instead analyzed the
complete chaperoning cycle involved in strand transfer (e.g.,
melting of stable stem-loop structures followed by annealing into
an hybrid heteroduplex). Acutissimin A (4a) was found to be the
most potent inhibitor of the series tested here. Lower activity was
found for acutissimin B (4b), which was further reduced in both
epiacutissimins (5a and 5b), thus indicating a selectivity in the
recognition of the protein target rather than non-speciﬁc effects.
Binding of acutissimins A and B (4a, 4b) and of epiacutissimin A
(5a) to NC was further conﬁrmed by mass spectrometry. All of the
other compounds shown in Fig. 3 were less active or inactive, with
a notable exception represented by ellagic acid (9), which however
exhibited a slightly different mechanism. In comparisonwith other
reported inhibitors2,19,20,33e36 the acutissimins exhibit a remark-
able anti-NC action in vitro, with a mechanism of action different
from that of intercalators and zinc-ejectors.
2. Results and discussion
2.1. Inhibition of NC-mediated stem melting of TAR and cTAR
The helix destabilization (or stem melting) activity of NC has
been exploited to set up a high throughput screening (HTS) to
identify in vitro inhibitors of NC.20,33 The assay is based on doubly
labeled oligonucleotides that manifest an increase of ﬂuorescence
as a result of NC’s helix destabilizing activity. As depicted in Fig. 4,
protein binding can induce dissociation of the lower half of the
stem, which increases the distance between ﬂuorophore and
quencher placed at the two ends of the construct.Fig. 4. Schematic representation of the NC-induced stem melting assay. The reporter
construct was labeled at the 50- and 30-end with a ﬂuorophore (yellow) and quencher
(dark), respectively. (A). The destabilization of nucleic acid secondary structure (i.e.,
stem melting) was evaluated by measuring the ﬂuorescence of the reporter, which was
expected to increase with the distance between donor and acceptor. (B) Addition of
inhibitor (P) prevented NC-induced melting, which resulted in dose-dependent de-
creases of the ﬂuorescence signal over the control. The assay was readily adapted to an
HTS format that enabled the rapid identiﬁcation and ranking of possible hits.After preliminary controls ensured the absence of direct
quenching activity by the compounds under investigation, their
ability to inhibit stem melting was evaluated in the presence of
recombinant HIV-1 NC (Fig. 4B). The results in Table 1 report the
half maximal inhibitory concentration (i.e., IC50) of helix de-
stabilization mediated by NC, respectively, on TAR (RNA) and cTAR
(DNA). Acutissimin A (4a), a water-soluble ﬂavano-ellagitannin in
which the C80 center of catechin is connected to the C1 center ofvescalagin (1, Fig. 3) was found to be among the most active com-
pounds with equivalent potency against TAR and cTAR stem
melting. Its a-epimer derived from epicatechin, epiacutissimin A
(5a), manifested very potent helix destabilization and exhibited
preferential inhibition of TAR melting. Acutissimin B (4b), in which
the C60 center of catechin is connected to the C1 center of vesca-
lagin, was also a positive hit on both substrates, while epi-
acutissimin B (5b), the a-epimer of 4b (Fig. 3), was active as cTAR
melting inhibitor but much less potent on TAR (Table 1).
Control experimentswere carried out to ensure that the activityof
acutissimins, among themost potent inhibitors in the series, was not
the result of undesirable NC precipitation. Considering that protein
precipitation is one of the classic criteria for evaluating the in-
teraction of polyphenols with cognate proteins,37 assays were con-
ducted after different incubation intervals, while examining the
samples for possible signs of precipitation. The TAR reporter was
monitored in three separate experiments conducted 5 min apart in
the presence of increasing amounts of 4a. The respective curves
shown in Fig. S1 (see Supplementary data) were perfectly superim-
posable and did not display the typical signal scatter that is a hall-
mark of protein precipitation (personal observation). Additional
controls were performed to verify whether the potent inhibition
displayed by acutissimins was just a general trait shared with other
related C-glucosidic ellagitannins, or a very distinctive feature of
these speciﬁcmolecules.Whenvescalagin (1) and castalagin (2)were
submitted to the stem-melting assay, they both exhibited much
lower activity on TARmelting, but only weak interferencewith cTAR
(DNA) melting. Catechin (3a) was totally inactive. Vescalin (6) and
castalin (7), which derive from hydrolysis of vescalagin and castala-
gin, respectively, were also totally inactive. Ellagic acid (9), which can
be released by hydrolytic cleavage of the 4,6-HHDP unit of both
vescalaginand castalagin,26 exhibited inhibitory properties thatwere
quite weak, albeit more pronounced when cTAR was the reporter.
The study included also three urolithins known as gut metabolites of
9, urolithin A (10a), urolithin B (10b), and the pentahydroxylated
urolithin known as M5 (10c).32 The urolithins 10b and 10c exhibited
limited inhibition, comparable to that of 9, whereas 10awas totally
inactive. Gallic acid (8) showed no activity (Table 1).
2.2. Acutissimins inhibit NC-mediated annealing of TAR and
cTAR
These preliminary experiments clearly suggested that the sim-
pliﬁcation of the structure of acutissimins to its constitutive
Table 2
NC annealing inhibition by NAME assay
Compound NC-preincubation Oligo-preincubation
Vescalagin (1) >50 >50
Castalagin (2) >50 47.40.3
Acutissimin A (4a) 26.40.8 21.50.3
Acutissimin B (4b) 34.60.7 33.10.5
Epiacutissimin A (5a) >50 31.22.0
Epiacutissimin B (5b) >50 >50
Ellagic acid (9) 40.82.1 >50
Urolithin B (10b) >50 >50
Urolithin M5 (10c) >50 >50
a Values are the meanSEM of three independent experiments.
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a possible mechanism of structure-speciﬁc inhibition. Among the
two acutissimins and their epimers, a few signiﬁcant differences
could be noted in the potency of stem-melting inhibition, with
epiacutissimin B (5b) being the least potent of the four related
compounds on TAR melting. This observation prompted further
evaluation of these inhibitors against other important aspects of
NC’s chaperone activity. In the case of TAR and cTAR, helix de-
stabilization is followed by strand annealing and eventual forma-
tion of a stable TAR/cTAR heteroduplex.12,38 Therefore, monitoring
the formation of dimeric species in the presence of protein offers
the opportunity to assess the inhibitory properties of the various
hits in the context of the entire structure remodeling process me-
diated by NC.
For this reason, we implemented the Nucleocapsid Annealing
Mediated Electrophoresis (NAME) assay to further characterize
acutissimins activity. Based on the different electrophoretic mo-
bility of individual nucleic acids structures, NAME does not require
ﬂuorescent labeling of oligonucleotide substrates, but rely instead
on the direct electrophoretic analysis of folded TAR and cTAR
constructs, readily differentiated from one another and from the
double-stranded TAR/cTAR hybrid produced by NC catalysis.20,39 In
selected experiments, the acutissimins were preincubated for
15 min with full-length recombinant NC, mixed with unlabeled/
prefolded TAR and cTAR, and ﬁnally incubated for an additional 15-
min interval (NC-preincubation mode).
The results shown in Fig. 5 clearly demonstrated the ability of
NC to mediate the complete formation of annealed TAR/cTAR
heteroduplex in the absence of acutissimins (lanes 4 and 10). In
contrast, inhibition of chaperone activity was evidenced by the
dose-dependent decrease of annealed heteroduplex in the pres-
ence of 4a and 4b (lanes 5e9 and 11e15), in parallel with the
detection of its individual cTAR and TAR component. The in-
hibitor 4a displayed greater potency than the corresponding 4b
species. This subtle difference of activity could be possibly as-
cribed to the different positions of their catechin units, which are
connected to the vescalagin core either through the C60 (4b) or
C80 (4a) center.Fig. 5. Nucleocapsid Annealing Mediated Electrophoresis (NAME) assay completed in
NC-preincubation mode (see Experimental section). Inhibition effects were evaluated
in the presence of increasing amounts of acutissimin A (4a) or acutissimin B (4b). The
full-length recombinant NC protein (8 mM) was preincubated with increasing con-
centrations (0, 1, 5, 10, 20, 50 mM ﬁnal) of each acutissimin for 15 min at room tem-
perature (lanes 4e9 and 10e15). TAR (1 mM) and cTAR (1 mM), folded separately and
then mixed together, were incubated with the NCeacutissimin solutions for 15 min at
room temperature. TAR (lane 1), cTAR (lane 2), and the hybrid TAR/cTAR (lane 3) were
used as controls.In other experiments, the acutissimins were preincubated with
recombinant NC prior tomixing with prefolded constructs and ﬁnal
incubation before analysis (oligo-preincubation mode, see Fig. S2).
Indeed, changing the mixing order while keeping overall in-
cubation time constant was expected to reveal possible variations
introduced by the different afﬁnity toward the protein or nucleic
acid structures. At the same time, the assays helped rank therelative potencies of a set of closely related compounds in slowing
down the very efﬁcient annealing activity of the protein. Under the
selected conditions, it was possible to calculate the inhibitory
concentration (IC50) for the NC-mediated annealing of TAR to cTAR,
reported in Table 2.Examined in either mode, acutissimins A (4a) and to a lower
extent acutissimin B (4b) exhibited similar inhibitory potency,
whereas the other inhibitors proved less efﬁcient in slowing NC-
mediated annealing. The behavior exhibited by such compounds
was consistent with the possible presence of distinctive molecular
interactions within the NCeoligo complexes. The fact that epi-
acutissimin A (5a), the epimer of 4a, was signiﬁcantly inﬂuenced by
oligo-preincubation (Table 2 and Fig. S3) suggests that extensive
contact may take place between the nucleic acid substrates and this
ellagitannin, perhaps through H-bonding and/or p-stacking. In-
terestingly, ellagic acid (9) proved to be relatively active in the
NAME assays. However, unlike the other ellagitannins tested, its
activity was higher upon preincubation with protein, thus in-
dicating a different mode of interaction with the nucleic acids-
protein complex (Table 2). In contrast, epiacutissimin B (5b) was
not inﬂuenced by the incubation mode (Table 2). This compound
displayed no activity within the range of concentrations surveyed
by NAME (i.e., up to 50 mM), in spite of its identiﬁcation by the
ﬂuorescence-based assay depicted in Fig. 4. Although we cannot
exclude that 5b may represent a false positive obtained by the
ﬂuorescence assay, we believe that its interaction with the
NCeoligo complex may lead to only partial inhibition of chaper-
oning activity, in contrast with the observations afforded by the
other acutissimins.
2.3. Acutissimins possess direct NC-binding activity
A careful comparison of the results provided by the different
approaches revealed subtle discrepancies in their conclusions. Both
NC-mediatedmelting and annealing assays consistently recognized
the same acutissimin structures (i.e., 4a and 4b) as the most potent
inhibitors in the study. In contrast, the assays showed some dis-
agreement on the potency of the respective epimeric structures.
Indeed, 5a was found to be a good annealing inhibitor when pre-
incubated with oligonucleotides, whereas its melting inhibition
capabilities were markedly different when TAR or cTAR were con-
sidered. Similarly, the weak annealing inhibitor 5b displayed very
low activity against TAR melting, but could be easily ranked as the
most potent compound for cTAR melting inhibition. Some of these
discrepancies could be explained by the possibility that the
ﬂuorescence-based assay may overestimate the inhibitory activity,
while the NAME approach may provide a more faithful
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NAME experiments were completed, suggested that the mecha-
nism of inhibition may involve direct binding of acutissimins to the
NC protein.
This hypothesis was tested by using electrospray ionization
mass spectrometry (ESI-MS) to evaluate the binding properties of
the species under consideration. This technique has been pre-
viously shown capable of detecting intact zinc-bound NC, as well as
its non-covalent complexes with various RNA substrates.40e42 The
possible formation of NCeacutissimin complexes wasmonitored by
adding increasing amounts of ligand to a ﬁxed concentration of
protein (see Experimental section). A preliminary determination of
the initial protein afforded an experimental mass of 6488.910 Da,
which matches very closely the monoisotopic value of 6488.906 Da
calculated from the sequence and including two bound Zn(II) ions
(not shown).40 Samples containing the different ligands afforded
different results, as shown by the representative spectra in Fig. 6. In
fact, a 1:1 complex between NC and acutissimin A was readily
detected with an experimental mass of 7695.011 Da, which
matches the monoisotopic value of 7695.040 Da calculated from
the sequence and elemental composition of the ligand (Fig. 6a). The
resolution achieved in these experiments allowed us to fullyFig. 6. Representative ESI-MS spectra of samples containing NC and (a) acutissimin A,
(b) acutissimin B, (c) epiacutissimin A, and (d) epiacutissimin B (see Experimental
section). For the sake of clarity, only the region containing the complex is shown.
The weaker signals near the main peak correspond to typical sodium adducts.resolve the isotopic distribution of the detected species, revealing
the charge state of individual ions and making data interpretation
unambiguous.
In similar fashion, 1:1 complexes were detected also for acu-
tissimin B and epiacutissimin A (Fig. 6b and c), respectively,
whereas no complex was observed for epiacutissimin B (Fig. 6d). It
is important to note that these epimeric compounds share the same
elemental composition and, thus, were detected with identical
masses. In all cases, the mass of the ellagitannineNC complex
matched those calculated by including two Zn(II) ions, thus ruling
out zinc ejection as a possible mechanism of inhibition. The pos-
sibility that multiple ligand equivalents may bind to the protein at
the same time was tested by increasing the amount of ellagitannin
in solution. Under these conditions, however, no additional binding
was observed. Furthermore, the abundance of the 1:1 complexes
did not appear to increase as the concentration of ligand was risen
up to 10:1 ligand to protein ratio (not shown). A direct comparison
of the observed abundances suggested a putative 4a>4by5a rel-
ative scale of binding afﬁnities, whichmatched the ranking order of
the annealing inhibition experiments. The fact that no binding ac-
tivity was observed for epiacutissimin B (5b) contradicted the cTAR
melting experiments and suggested that a strong DNA interaction
may be the source of those results. Further experiments are in
progress to answer to this question.
3. Conclusion
Our screening program has positively identiﬁed several ellagi-
tannins as putative in vitro inhibitors of HIV-1 NC activity. Among
this class of plant polyphenols present in wine aged in oak barrels,
acutissimins have emerged as potent inhibitors of melting and
annealing capabilities, as revealed by assays involving the TAR/
cTAR system. In particular, acutissimin A (4a) was the most active
compound identiﬁed by NAME assays, while its a-epimer epi-
acutissimin A (5a) was weaker, consistent with the lower binding
afﬁnity toward NC detected by ESI-MS experiments. The
regioisomer acutissimin B (4b) was slightly less active than acu-
tissimin A (4a), while its a-epimer epiacutissimin B (5b) was unable
to bind NC and inactive in the annealing inhibition assay. Although
strong evidencewas obtained of direct interactions between 4a, 4b,
5a and NC in its zinc-bound form, no binding was observed for 5b
under the selected experimental conditions. The fact that this
compound induced melting inhibition when DNA oligonucleotides
were used as substrates suggests that this polyphenol may estab-
lish direct interactions with the nucleic acids. Further studies are
underway to identify the molecular determinants that confer to
these compounds their excellent ability to interfere with NC
chaperoning of TAR and cTAR.
In this direction, it is important to consider that the constituting
units of the acutissimin structures and closely related compounds
are simpler polyphenols, which are also present in wine, but were
found to possess only limited or no activity whatsoever. The activity
of vescalagin (1) and its a-epimer castalagin (2) was negligible in
NAME assays, while vescalin (6), castalin (7), and catechin (3a)
were found inactive against NC, thus providing further proof of the
important role played by the higher structural complexity, in-
cluding overall size and shape, in the recognition of the protein
target. For this reason, it is not surprising that acutissimins have
been shown to induce speciﬁc inhibition of other nucleic acid-
binding proteins, such as the human topoisomerase IIa.26,43
Ellagic acid (9), the bislactone produced from the hydrolytic
cleavage of ellagitannin HHDP units, was also identiﬁed among the
hits and conﬁrmed to inhibit NC-mediated annealing. In contrast
with the other compounds, NAME assays showed that the in-
hibitory activity of this simpler but not water-soluble polyphenol
was negatively affected by preincubation with nucleic acids. This
A. Sosic et al. / Tetrahedron 71 (2015) 3020e3026 3025small and planar structure is perhaps better suited to interact di-
rectly with the hydrophobic cavity of NC, possibly by stacking with
the aromatic side chains in the zinc ﬁngers. Interestingly, the
monolactonic urolithin metabolites of ellagic acid were also found
to possess no activity by our tests.
The low concentrations of acutissimins in wine (0.30e0.40 mg/
L)28 clearly rule out any claim that wine might serve as an alter-
native remedy for HIV. Our study employed in vitro approaches
that aimed at recognizing active hits amenable to further de-
velopment in drug discovery programs. The outcome indicated
that these natural structures constitute valuable scaffolds for NC
protein inhibition, which are distinct in molecular complexity
from other classes of molecules that have been proposed as pos-
sible anti-NC agents. Further studies are underway to investigate
their activity in infected cells to fully evaluate their antiviral po-
tential. We hope that this study will foster the interest in plant
polyphenols as a source of inspiration for the discovery of new NC
inhibitors.
4. Experimental section
4.1. Materials
The four acutissimins were hemisynthesized from ()-vescala-
gin (1) and (þ)-catechin (3a) or ()epicatechin (3b), as previously
described.26,27 ()-Vescalin (6) and (þ)-castalin (7) were prepared
by acidic hydrolysis of ()-vescalagin (1) and ()-castalagin (2), as
previously described.26 (þ)-Catechin (3a), ellagic acid (9), and gallic
acid (8) were purchased from SigmaeAldrich, while urolithins were
a kind gift of Prof. Zagotto (University of Padova).44,45
All oligonucleotides were synthesized by Metabion In-
ternational AG (Martinsried, Germany) and stored at 20 C in
10 mM TriseHCl, pH 7.5. Dilutions were made in DEPC-treated
water (Ambion). TAR is the 29-mer RNA sequence 50-GGCAGAU-
CUGAGCCUGGGAGCUCUCUGCC-30 and cTAR is its DNA comple-
mentary sequence 50-GGCAGAGAGCTCCCAGGCTCAGATCTGCC-30.
When speciﬁed, TAR and cTAR were labeled at 50 and 30 ends, re-
spectively, by the ﬂuorophore 5-carboxyﬂuorescein (FAM) and the
dark quencher 4-(40-dimethylaminophenylazo)benzoic acid
(Dabcyl).
The full-length recombinant NC protein was obtained as pre-
viously reported.46 The protein concentration was determined on
a UVevis Spectrophotometer Lambda 20, PerkinElmer, using an
extinction coefﬁcient at 280 nm of 6410 M1 cm1.
4.2. Inhibition of NC-induced stem melting (helix
destabilization)
Thestemmeltingassay (orhigh throughput screeningdHTS)was
performed to identify inhibitors of NC chaperone activity both on
TAR and cTAR. We used a microplate reader VictorIII (PerkinElmer)
with 485 and 535 nm as excitation and emission wavelengths.
50-FAMand 30-DABmodiﬁed TARor cTAR (each 1 mM)were folded in
TNMg (TriseHCl 10 mM, NaCl 20 mM, Mg(ClO4)2 1 mM pH 7.5): the
oligonucleotides were denatured at 95 C for 5 min and then left to
cool to room temperature in order to assume their stem-bulge-loop
structure. cTAR or TAR was then diluted to 0.1 mM in TN (TriseHCl
10mM,NaCl 20mMpH7.5). Increasing concentrations of compound
(0, 0.1, 0.5,1, 5,10, 50,100 mMﬁnal)were incubatedwith 0.1 mMcTAR
or TAR in each well. Finally, NC 0.8 mM (molar ratio oligos/NC¼1:8)
was added to each sample. The plate was read three times with
a delay of 1 min one reading from the other, unless differently
speciﬁed. The experimental datawereﬁtted as reported and the IC50
value was calculated for each compound.20 Each experiment was
performed in triplicate to calculate a standard deviation of the IC50
value.4.3. Inhibition of TAR/cTAR annealing by polyphenols
Nucleocapsid Annealing Mediated Electrophoresis (NAME) as-
say was developed to investigate the ability of compounds to im-
pair the biological activity of the full-length NC protein, monitoring
the annealing of TAR with cTAR. TAR, cTAR, and the hybrid TAR/
cTAR (each 1 mM) each folded in TNMg (TriseHCl 10 mM, NaCl
20 mM, Mg(ClO4)2 1 mM pH 7.5) were used as controls: the oli-
gonucleotides were denatured at 95 C for 5 min and then left to
cool to room temperature in order to assume their stem-bulge-loop
(TAR and cTAR) or double-stranded (hybrid TAR/cTAR) structure. To
evaluate the inhibition of NC-mediated TAR/cTAR hybrid formation
two different assay formats were exploited.
4.3.1. NC-preincubation. The full-length recombinant NC protein
(8 mM) was preincubated with increasing concentrations (0, 1, 5, 10,
20, 50 mM compound ﬁnal concentrations) of each polyphenol for
15 min at room temperature. TAR (1 mM) and cTAR (1 mM), folded
separately as described above and then mixed together, were in-
cubated with the NCepolyphenol solutions for 15 min at room
temperature. Gel Loading Buffer containing SDS (GLBSDS: TriseHCl
100 mM, EDTA 4 mM, 50% w/v glycerol, 2% w/v SDS, 0.05% w/v
bromophenol blue), was added to the samples, that were then kept
on ice and ﬁnally resolved on a 12% native PAGE (acrylamide/
bisacrylamide¼19:1), run in TBE buffer (Tris 89 mM, boric acid
89 mM, and EDTA 2 mM, pH 8) for 3 h at 200 V.
4.3.2. Oligo-preincubation. TAR (1 mM) and cTAR (1 mM) were fol-
ded separately as described above and then individually pre-
incubated with increasing concentrations of compound (each oligo
with 0, 1, 5, 10, 20, 50 mM compound ﬁnal concentrations) for
15 min at room temperature, then mixed together and added of NC
solution (8 mM) and incubated for other 15 min at room tempera-
ture. Gel Loading Buffer containing SDS (GLBSDS: TriseHCl 100 mM,
EDTA 4 mM, 50% w/v glycerol, 2% w/v SDS, 0.05% w/v bromophenol
blue), was added to the samples, that were then kept on ice and
ﬁnally resolved on a 12% native PAGE (acrylamide/
bisacrylamide¼19:1), run in TBE buffer (Tris 89 mM, boric acid
89 mM, and EDTA 2 mM, pH 8) for 3 h at 200 V.
After electrophoresis, the gels were stained with SybrGreen II
and detected on a Geliance 600 Imaging System (PerkinElmer). In
both cases, the IC50 (concentration of the compound required to
inhibit the hybrid formation by half) was calculated by the quan-
tiﬁcation (using GeneTools software from PerkinElmer) of the
percentage of the hybrid formation.
4.4. AcutissiminseNC binding analysis
Samples for the binding studies were prepared by mixing ap-
propriate volumes of stock solution of NC (2 mM ﬁnal) with each
compound in 150 mM ammonium acetate (pH 7.5). The ﬁnal mix-
tures contained up to a 10:1 compound/NC molar ratio. In order to
ensure the binding equilibrium in solution before analysis, the
samples were incubated for 10 min at room temperature. Control
experiments were performed by using a solution of NC protein in
150 mM ammonium. All samples were analyzed by direct infusion
ESI on a Thermo Fisher Scientiﬁc (West Palm Beach, CA) LTQ-
Orbitrap Velos mass spectrometer. The analyses were performed
in nanoﬂow ESI mode by using quartz emitters produced in-house
by a Sutter Instruments Co. (Novato, CA) P2000 laser pipette puller.
Up to 7 mL samples were loaded onto each emitter by using a gel-
loader pipette tip. A stainless steel wire was inserted in the back-
end of the emitter and used to supply an ionizing voltage ranged
around 0.8e1.1 kV. Source temperature and desolvation conditions
were adjusted by closely monitoring the incidence of ammonium
adducts and water clusters, with typical source temperature of
A. Sosic et al. / Tetrahedron 71 (2015) 3020e30263026200 C. Data were processed by using Xcalibur 2.1 software by
Thermo Scientiﬁc.
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